Chromadex Corp (NASDAQ:CDXC) Expected to Post Quarterly Sales of $10.80 Million

Wall Street brokerages expect Chromadex Corp (NASDAQ:CDXC) to post $10.80 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Chromadex’s earnings, with estimates ranging from $10.61 million to $11.00 million. Chromadex posted sales of $7.80 million in the same quarter last year, which would indicate a positive year over year growth rate of 38.5%. The company is expected to report its next earnings report on Thursday, August 8th.

According to Zacks, analysts expect that Chromadex will report full year sales of $47.13 million for the current year, with estimates ranging from $45.22 million to $49.05 million. For the next financial year, analysts expect that the firm will report sales of $83.71 million, with estimates ranging from $67.42 million to $100.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Chromadex.

Chromadex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). The firm had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9.80 million. Chromadex had a negative net margin of 94.78% and a negative return on equity of 108.84%.

CDXC has been the topic of a number of research reports. Zacks Investment Research cut Haynes International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. HC Wainwright set a $55.00 price objective on Acer Therapeutics and gave the company a “buy” rating in a research report on Tuesday, May 28th. ValuEngine cut Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 25th. Finally, BidaskClub cut Zebra Technologies from a “hold” rating to a “sell” rating in a research report on Friday, May 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Chromadex has a consensus rating of “Hold” and a consensus price target of $6.00.

Shares of CDXC traded down $0.06 on Friday, reaching $4.41. 172,857 shares of the stock traded hands, compared to its average volume of 367,462. The firm has a market cap of $248.18 million, a price-to-earnings ratio of -7.23 and a beta of 1.26. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.68 and a current ratio of 2.24. Chromadex has a 12 month low of $2.79 and a 12 month high of $5.00. The stock’s 50-day moving average is $4.21.

A number of large investors have recently made changes to their positions in CDXC. BNP Paribas Arbitrage SA acquired a new position in Chromadex in the first quarter worth $34,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in Chromadex in the first quarter worth $42,000. Spark Investment Management LLC acquired a new position in Chromadex in the first quarter worth $78,000. Rhumbline Advisers boosted its stake in Chromadex by 53.3% in the fourth quarter. Rhumbline Advisers now owns 48,511 shares of the company’s stock worth $166,000 after purchasing an additional 16,863 shares in the last quarter. Finally, Miracle Mile Advisors LLC acquired a new position in Chromadex in the first quarter worth $272,000. Hedge funds and other institutional investors own 18.11% of the company’s stock.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

See Also: Return on Equity (ROE)

Get a free copy of the Zacks research report on Chromadex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.